OUR PEOPLE

A trusted team. A proven track record.

Elion Therapeutics leadership possesses more than 200 years of collective academic, chemistry, nonclinical, clinical, manufacturing, and regulatory experience in the development of almost every antifungal agent available today. We are excited to carry this legacy forward with SF001.

Leadership team

Leadership team

Image link

Kieren Marr
MD, MBA, FIDSA

President and Chief Medical Officer

VIEW BIO
Image link

Carmen Betancourt-Riche
MBA

Regulatory Affairs and Quality Assurance

VIEW BIO
Image link

Laura A. Navalta

Clinical Operations

VIEW BIO
Image link

Scott Reynolds
PhD

Chemistry, Manufacturing, and Controls

VIEW BIO
Image link

Georgina Kilfoil
MBA

Project Management

VIEW BIO

Board of directors

Kieren Marr

Elion Therapeutics

Martin Heidecker

AMR Action Fund

Jim Flynn

Deerfield Management Company

Jonathan Ramos

Deerfield Management Company

Jonathan Leff

Deerfield Management Company

Investors

AMR Action Fund

The AMR Action Fund is a mission-driven venture capital fund investing in antibiotics, antifungals, and other antimicrobial technologies. The Fund plans to invest approximately US$1 billion into clinical-stage biotech companies to help bring two to four new antibiotics to market by 2030.

Deerfield Management Company

Launched in 1994, Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways. For more information, visit deerfield.com.

Illinois Ventures

Launched in 2000, Illinois Ventures manages return-focused venture funds and is an evergreen fund for seed-stage start-ups from the University of Illinois system.

The namesake of Elion Therapeutics is the Nobel Prize winner Gertrude B. Elion (1918-1999), a pioneer in rational drug design. Her scientific dedication and legacy provide enduring inspiration to this day.